垂体受体 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
==== Dark Messiah of Might and Magic (2006) and cancelled projects ==== Antonov joined French developer Arkane Studios. He was a level designer for their 2006 action role-playing game (RPG) Dark Messiah of Might And Magic, helping his team replicate Valve's process of making levels for Half-Life 2. Around 2007 and 2008, Arkane began developing an officially licensed Half-Life sequel, centered around the alien zombies that infest the ghost town of Ravenholm in Half-Life 2. Antonov continued helping Arkane replicate Valve's design process. The project was soon scrapped, because they did not develop it in the time that Valve wanted, and Valve was having trouble deciding where Half-Life as a series should go while making its episodic entries. Arkane's then-president Raphaël Colantonio has said that Antonov's work on the project "was pivotal to what would become Arkane later", as "he trained us in all of [Valve's] practices in terms of art, in terms of how to think of a level, [and] how to think of architecture". Antonov was a level designer for the studio's next project, an FPS titled The Crossing, for which he created a sci-fi version of Paris. In 2009, this project was also cancelled, as Arkane was unable to secure financing for it, as well as a publisher that would let them retain the game's intellectual property rights in the future. However, elements of The Crossing later came to fruition in Arkane's 2021 FPS Deathloop.
==== Microbial metabolism ==== Biological deuterium fractionation through metabolism is very organism and pathway dependent, resulting in a wide variability in fractionations. Despite this, some trends still hold. Hydrogen isotopes tend to fractionate very strongly in autotrophs relative to heterotrophs during lipid biosynthesis - chemoautotrophs produce extremely depleted lipids, with the fractionation ranging from roughly −200 to −400‰. This has been observed both in laboratory-grown cultures fed a known quantity of deuterated water and in the environment. Proteins, however, do not follow as significant a trend, with both heterotrophs and autotrophs capable of generating large and variable fractionations. In part, kinetic fractionation of the lighter isotope during formation of reducing equivalents NADH and NADPH result in lipids and proteins that are isotopically lighter. Salinity appears to play a role in the degree of deuterium fractionation as well; more saline waters affect growth rate, the rate of hydrogen exchange, and evaporation rate. All of these factors influence lipid δD upon hydrogen being incorporated into biomass. In coccolithophores Emiliania huxleyi and Gephyrocapsa oceanica, alkenone δD has been found to correlate strongly to organism growth rate divided by salinity. The relationship between deuterium fractionation and salinity could potentially be used in paleoenvironment reconstruction with preserved lipids in the rock record to determine, for example, ocean salinity at the time of organismal growth.
Ethanol (alcohol) is first converted into acetaldehyde, consuming NAD+ twice, before being converted into acetate. The acetate is then converted into acetyl-CoA. When alcohol is consumed in small quantities, the NADH/NAD+ ratio remains in balance enough for the acetyl-CoA to be used by the Krebs cycle for oxidative phosphorylation. However, even moderate amounts of alcohol (1-2 drinks) results in more NADH than NAD+, which inhibits oxidative phosphorylation. When the NADH/NAD+ ratio is disrupted (far more NADH than NAD+), this is called pseudohypoxia. The Krebs cycle needs NAD+ as well as oxygen, for oxidative phosphorylation. Without sufficient NAD+, the impaired aerobic metabolism mimics hypoxia (insufficient oxygen), resulting in excessive use of anaerobic glycolysis and a disrupted pyruvate/lactate ratio (low pyruvate, high lactate). The conversion of pyruvate into lactate produces NAD+, but only enough to maintain anaerobic glycolysis. In chronic excessive alcohol consumption (alcoholism), the microsomal ethanol oxidizing system (MEOS) is used in addition to alcohol dehydrogenase.
In the second phase, British fortunes changed when their commanding officer, General Redvers Buller, was replaced by Lord Roberts and Lord Kitchener, who relieved the besieged cities and invaded the Boer republics at the head of a 180,000-strong expeditionary force. The Boers, aware that they were unable to resist such a force, refrained from fighting pitched battles, thereby allowing the British to occupy both republics and their capitals. Boer politicians fled or went into hiding; the British annexed the two republics in 1900. In Britain, the Conservative ministry attempted to capitalise by calling an early general election, dubbed a "khaki election". In the third phase, Boer fighters launched a guerrilla campaign. They used hit-and-run attacks and ambushes against the British for two years. The guerrilla campaign proved difficult for the British to defeat, due to unfamiliarity with tactics and support among civilians. British high command ordered scorched earth policies as part of a counterinsurgency campaign. Over 100,000 Boer civilians were forcibly relocated into concentration camps, where 26,000 died, by starvation and disease. Native Africans were interned to prevent them from supplying the Boers; 20,000 died. British mounted infantry were deployed to track down guerrillas, and few combatants were killed in action, most dying from disease. Kitchener offered terms to remaining Boer leaders to end the conflict. Eager to ensure Boers were released from the camps, most Boer commanders accepted the terms in the Treaty of Vereeniging, surrendering in May 1902.
Sources: en.wikipedia.org
Familial: Family history of hirsutism with normal androgen levels. Drug-induced: medications were used before the onset of hirsutism. The recommendation is to stop the medication and replace it with another. Minoxidil Androgens like testosterone, anabolic steroids, and androgenic progestins Valproic acid and methyldopa Pregnancy: Due to changes in hormone production Idiopathic: When no other cause can be attributed to an individual's hirsutism, the cause is considered idiopathic by exclusion. In these cases, menstrual cycles and levels of conventionally tested androgens (testosterone, androstenedione, and dehydroepiandrosterone sulfate) are normal. Around 10 to 15% of women with hirsutism have idiopathic hirsutism. Idiopathic hirsutism may be due to increased production of dihydrotestosterone (DHT) in hair follicles and hence may actually still be due to hyperandrogenism. It may be detectable by measurement of DHT or DHT metabolites. Rice et al. 2016 propose that idiopathic hirsutism is caused by epigenetic inheritance of discordant epigenetic markers. It is testable with current technology.
=== EC 1.14.19 With oxidation of a pair of donors resulting in the reduction of O2 to two molecules of water === EC 1.14.19.1: stearoyl-CoA 9-desaturase EC 1.14.19.2: stearoyl-[acyl-carrier-protein] 9-desaturase EC 1.14.19.3: linoleoyl-CoA desaturase EC 1.14.19.4: acyl-lipid (11-3)-desaturase EC 1.14.19.5: acyl-CoA 11-(Z)-desaturase EC 1.14.19.6: acyl-CoA (9+3)-desaturase EC 1.14.19.7: Now EC 1.11.1.23, (S)-2-hydroxypropylphosphonic acid epoxidase EC 1.14.19.8: pentalenolactone synthase EC 1.14.19.9: tryptophan 7-halogenase EC 1.14.19.10: icosanoyl-CoA 5-desaturase EC 1.14.19.11: acyl-[acyl-carrier-protein] 4-desaturase EC 1.14.19.12: acyl-lipid ω-(9-4) desaturase EC 1.14.19.13: acyl-CoA 15-desaturase EC 1.14.19.14: linoleoyl-lipid Δ9 conjugase EC 1.14.19.15: (11Z)-hexadec-11-enoyl-CoA conjugase EC 1.14.19.16: linoleoyl-lipid Δ12 conjugase (11E,13Z-forming) EC 1.14.19.17: sphingolipid 4-desaturase EC 1.14.19.18: sphingolipid 8-(E)-desaturase EC 1.14.19.19: sphingolipid 10-desaturase EC 1.14.19.20: Δ7-sterol 5(6)-desaturase EC 1.14.19.21: cholesterol 7-desaturase EC 1.14.19.22: acyl-lipid ω-6 desaturase (cytochrome b5) EC 1.14.19.23: acyl-lipid (n+3)-(Z)-desaturase (ferredoxin) EC 1.14.19.24: acyl-CoA 11-(E)-desaturase EC 1.14.19.25: acyl-lipid ω-3 desaturase (cytochrome b5) EC 1.14.19.26: acyl-[acyl-carrier-protein] 6-desaturase EC 1.14.19.27: sn-2 palmitoyl-lipid 9-desaturase EC 1.14.19.28: sn-1 stearoyl-lipid 9-desaturase EC 1.14.19.29: sphingolipid 8-(E/Z)-desaturase EC 1.14.19.30: acyl-lipid (8-3)-desaturase EC 1.14.19.31: acyl-lipid (7-3)-desaturase EC 1.14.19.32: palmitoyl-CoA 14-(E/Z)-desaturase EC 1.14.19.33: Δ12 acyl-lipid conjugase (11E,13E-forming) EC 1.14.19.34: acyl-lipid (9+3)-(E)-desaturase EC 1.14.19.35: sn-2 acyl-lipid ω-3 desaturase (ferredoxin) EC 1.14.19.36: sn-1 acyl-lipid ω-3 desaturase (ferredoxin) EC 1.14.19.37: acyl-CoA 5-desaturase EC 1.14.19.38: acyl-lipid Δ6-acetylenase EC 1.14.19.39: acyl-lipid Δ12-acetylenase EC 1.14.19.40: hex-5-enoyl-[acyl-carrier protein] acetylenase EC 1.14.19.41: sterol 22-desaturase EC 1.14.19.42: palmitoyl-[glycerolipid] 7-desaturase EC 1.14.19.43: palmitoyl-[glycerolipid] 3-(E)-desaturase EC 1.14.19.44: acyl-CoA (8-3)-desaturase EC 1.14.19.45: sn-1 oleoyl-lipid 12-desaturase EC 1.14.19.46: sn-1 linoleoyl-lipid 6-desaturase EC 1.14.19.47: acyl-lipid (9-3)-desaturase EC 1.14.19.48: tert-amyl alcohol desaturase EC 1.14.19.49: tetracycline 7-halogenase EC 1.14.19.50: noroxomaritidine synthase EC 1.14.19.51: (S)-corytuberine synthase EC 1.14.19.52: camalexin synthase EC 1.14.19.53: all-trans-retinol 3,4-desaturase EC 1.14.19.54: 1,2-dehydroreticuline synthase EC 1.14.19.55: 4-hydroxybenzoate brominase (decarboxylating) EC 1.14.19.56: 1H-pyrrole-2-carbonyl-[peptidyl-carrier protein] chlorinase EC 1.14.19.57: 1H-pyrrole-2-carbonyl-[peptidyl-carrier protein] brominase EC 1.14.19.58: tryptophan 5-halogenase EC 1.14.19.59: tryptophan 6-halogenase EC 1.14.19.60: 7-chloro-L-tryptophan 6-halogenase EC 1.14.19.61: dihydrorhizobitoxine desaturase EC 1.14.19.62: secologanin synthase EC 1.14.19.63: pseudobaptigenin synthase EC 1.14.19.64: (S)-stylopine synthase EC 1.14.19.65: (S)-cheilanthifoline synthase EC 1.14.19.66: berbamunine synthase EC 1.14.19.67: salutaridine synthase EC 1.14.19.68: (S)-canadine synthase EC 1.14.19.69: biflaviolin synthase EC 1.14.19.70: mycocyclosin synthase EC 1.14.19.71: fumitremorgin C synthase EC 1.14.19.72: (–)-pluviatolide synthase EC 1.14.19.73: (S)-nandinine synthase EC 1.14.19.74: (+)-piperitol/(+)-sesamin synthase EC 1.14.19.75: very-long-chain acyl-lipid ω-9 desaturase EC 1.14.19.76: flavone synthase II EC 1.14.19.77: plasmanylethanolamine desaturase EC 1.14.19.78: decanoyl-[acyl-carrier protein] acetylenase
The ideal relationship between products and reactants in a chemical reaction can be obtained by using a chemical reaction equation. Stoichiometry is used to run calculations about chemical reactions, for example, the stoichiometric mole ratio between reactants and products. The stoichiometry of a chemical reaction is based on chemical formulas and equations that provide the quantitative relation between the number of moles of various products and reactants, including yields. Stoichiometric equations are used to determine the limiting reagent or reactant—the reactant that is completely consumed in a reaction. The limiting reagent determines the theoretical yield—the relative quantity of moles of reactants and the product formed in a chemical reaction. Other reactants are said to be present in excess. The actual yield—the quantity physically obtained from a chemical reaction conducted in a laboratory—is often less than the theoretical yield. The theoretical yield is what would be obtained if all of the limiting reagent reacted to give the product in question. A more accurate yield is measured based on how much product was actually produced versus how much could be produced. The ratio of the theoretical yield and the actual yield results in a percent yield. When more than one reactant participates in a reaction, the yield is usually calculated based on the amount of the limiting reactant, whose amount is less than stoichiometrically equivalent (or just equivalent) to the amounts of all other reactants present.
== Clinical significance == Patients with rosacea have elevated levels of cathelicidin and elevated levels of stratum corneum tryptic enzymes (SCTEs). Cathelicidin is cleaved into the antimicrobial peptide LL-37 by both kallikrein 5 and kallikrein 7 serine proteases. Excessive production of LL-37 is suspected to be a contributing cause in all subtypes of Rosacea. Antibiotics have been used in the past to treat rosacea, but antibiotics may only work because they inhibit some SCTEs. Lower plasma levels of human cathelicidin antimicrobial protein (hCAP18) appear to significantly increase the risk of death from infection in dialysis patients. The production of cathelicidin is up-regulated by vitamin D. SAAP-148 (a synthetic antimicrobial and antibiofilm peptide) is a modified version of LL-37 that has enhanced antimicrobial activities compared to LL-37. In particular, SAAP-148 was more efficient in killing bacteria under physiological conditions. In addition, SAAP-148 synergises with the repurposed antibiotic halicin against antibiotic-resistant bacteria and biofilms. LL-37 is thought to play a role in psoriasis pathogenesis (along with other anti-microbial peptides). In psoriasis, damaged keratinocytes release LL-37 which forms complexes with self-genetic material (DNA or RNA) from other cells. These complexes stimulate dendritic cells (a type of antigen presenting cell) which then release interferon α and β which contributes to differentiation of T-cells and continued inflammation.
=== Glutaminolysis and transamination === Aside from the citric acid cycle, α-ketoglutarate is made by glutaminolysis in which the enzyme glutaminase removes the amino group from glutamine to form glutamate which is converted to α-ketoglutarate by any one of three enzymes, glutamate dehydrogenase, alanine transaminase, or aspartate transaminase (see The glutaminolytic pathways). It is also made through the action of pyridoxal phosphate-dependent enzymes (alanine transaminase) in which glutamate is converted to α-Ketoglutarate by "donating" its −NH2 to other compounds (see transamination). These reactions are reversible. In the reverse direction of these reactions, α-ketoglutarate contributes to the production of amino acids such as glutamine, proline, arginine, and lysine as well as the lowering of cellular carbon and nitrogen (i.e., N) levels; this prevents excessive levels of these two potentially toxic elements from accumulating in cells and tissues. The neurotoxin, ammonia (i.e., NH3), is also prevented from accumulating in tissues. In this metabolic pathway the −NH2 group on an amino acid is transferred to α-ketoglutarate; this forms the α-keto acid of the original amino acid and the amine-containing product of α-ketoglutarate, glutamate. The cellular glutamate passes into the circulation and is taken up by the liver where it delivers its acquired −NH2 group to the urea cycle. In effect, the latter pathway removes excess ammonia from the body in the form of urinary urea.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。